デービック症候群治療市場：治療法別、流通チャネル別、エンドユーザー別 - 2025-2030年の世界予測

デービック症候群治療市場は、2023年に2億1,053万米ドルと評価され、2024年には2億2,027万米ドルに達すると予測され、CAGR 4.68％で成長し、2030年には2億9,003万米ドルに達すると予測されています。

視神経脊髄炎スペクトラム障害（NMOSD）としても知られるデービック症候群は、視神経と脊髄の炎症と脱髄を特徴とする自己免疫疾患です。その治療市場は、認知度の向上、有病率の上昇、早期診断を可能にする医療技術の進歩により拡大しています。治療の必要性は、慢性的で再発しやすいというこの病気の性質から生じており、治療を行わなければ重篤な障害をもたらす可能性があります。治療アプローチには、血漿交換、免疫抑制療法、エクリズマブのようなモノクローナル抗体があり、この疾患の根本的な発症メカニズムをターゲットとしています。最終用途のセグメントには、病院、専門クリニック、研究機関が含まれ、急性症例の管理に総合的な能力を持つ病院が大きなシェアを占めています。

市場促進要因は、患者数の増加とヘルスケア支出の増加です。共同研究イニシアチブの高まりがイノベーションをさらに後押しし、バイオテクノロジーがより効果的な治療オプションへの道を開く。しかし、市場は高い治療費、承認された治療薬の数の少なさ、開発パイプラインを阻害する規制上のハードルといった課題に直面しています。潜在的なビジネスチャンスは、戦略的パートナーシップ、個別化医療への投資、認知度や診断率が低い新興市場の未開発の可能性を探ることにあります。

とはいえ、発展途上地域におけるNMOSDの認知度の低さと臨床試験の複雑さが大きな障害となっています。事業成長のためには、早期発見、治療効果向上、患者転帰のためのバイオマーカー開発が有望な技術革新分野です。市場の競合情勢を考察すると、主に強力な研究開発能力と戦略的提携を有する主要製薬企業が優位を占めています。企業は、こうした機会をうまく活用するために、ヘルスケア・エコシステム全体にわたる協力関係の促進、サプライチェーンの最適化、アフォーダビリティ・プログラムによる患者アクセスの向上に注力すべきです。

市場力学：急速に進化するデービック症候群治療市場における主要市場インサイトの解明

デービック症候群治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • デービック症候群の世界の増加
  • 神経疾患に対する意識向上への取り組みと擁護団体の出現
  • デービック症候群治療へのアクセスを確保するための有利な規制当局の承認と政府の取り組み
• 市場抑制要因
  • デービック症候群は複雑な疾患であり、治療法が確立されていないです。
• 市場機会
  • デービック症候群治療ソリューションの有効性と安全性を向上させるための継続的な取り組み
  • 個別化された特異的な治療戦略に対する患者の嗜好
• 市場の課題
  • デービック症候群治療ソリューションの副作用の可能性

ポーターのファイブフォース：デービック症候群治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：デービック症候群治療市場における外部からの影響の把握

外部マクロ環境要因は、デービック症候群治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析デービック症候群治療市場における競合情勢の把握

デービック症候群治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスデービック症候群治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニング・マトリックスは、デービック症候群治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨デービック症候群治療市場における成功への道筋を描く

デービック症候群治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開発の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でデービック症候群の発生が増加
    • 神経疾患に対する意識を高める取り組みと支援団体の出現
    • デービック症候群の治療へのアクセスを確保するための好ましい規制承認と政府の取り組み
  • 抑制要因
    • 病気の複雑さとデービック症候群に対処する治療法の無力さ
  • 機会
    • デービック症候群治療ソリューションの有効性と安全性を向上させるための継続的な取り組み
    • 患者は個別化された特定の治療戦略を好む
  • 課題
    • デービック症候群の治療薬の副作用の可能性
• 市場セグメンテーション分析
  • 治療法：デービック症候群では、炎症を速やかに抑える効果があるため、コルチコステロイドを使用します。
  • エンドユーザー：成人患者向けの包括的なデービック症候群治療計画の開発
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 デービック症候群治療市場：治療法別

• コルチコステロイド
• 免疫抑制剤
• 血漿交換（血漿交換療法）

第7章 デービック症候群治療市場：流通チャネル別

• クリニック
• 病院
• オンライン薬局

第8章 デービック症候群治療市場：エンドユーザー別

• 成人
• 小児

第9章 南北アメリカのデービック症候群治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のデービック症候群治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのデービック症候群治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDAが視神経脊髄炎スペクトラム障害の治療薬ウルトミリスを承認、治療範囲を拡大
  • カナダ保健省、NMOSDの成人患者にUPLIZNAを承認
  • 中外製薬のNMOSD患者向けエンスプリングが台湾で発売
• 戦略分析と提言

企業一覧

• Accord Healthcare, Inc.
• Alexion Pharmaceuticals, Inc by AstraZeneca PLC
• Anant Pharmaceuticals Pvt. Ltd.
• Apple Pharmaceuticals
• Cadila Pharmaceuticals Limited
• Chugai Pharma Taiwan Ltd.
• Conscientia Industrial Co., Ltd
• Evidentic GmbH
• F. Hoffmann-La Roche Ltd
• Healthy Life Pharma Pvt. Ltd.
• Horizon Therapeutics plc by Amgen, Inc.
• LEXICARE PHARMA PVT. LTD.
• Merck KGaA
• Mitsubishi Tanabe Pharma Corporation
• Opexa Therapeutics, Inc.
• Samsung Bioepis Co., Ltd. by Samsung Biologics
• Teva Pharmaceutical Industries Ltd.
• TG Therapeutics, Inc.
• Thermo Fisher Scientific Inc.
• West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC

LIST OF FIGURES

• FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DEVIC'S SYNDROME TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Devic's Syndrome Treatment Market was valued at USD 210.53 million in 2023, expected to reach USD 220.27 million in 2024, and is projected to grow at a CAGR of 4.68%, to USD 290.03 million by 2030.

Devic's Syndrome, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD), is an autoimmune condition characterized by the inflammation and demyelination of the optic nerve and spinal cord. The scope for its treatment market is expanding due to increased awareness, rising prevalence, and advancements in medical technology enabling earlier diagnosis. The necessity for treatment arises from the chronic and relapsing nature of the disease, which can result in severe disability without intervention. The treatment approaches encompass plasma exchange, immunosuppressive therapies, and monoclonal antibodies like eculizumab, targeting the disease's underlying pathogenic mechanisms. End-use segments include hospitals, specialty clinics, and research institutes, with hospitals taking a significant share due to their comprehensive capabilities in managing acute cases.

Market growth is propelled by ongoing research and the introduction of novel therapeutics, while key drivers include a growing patient pool and increased healthcare spending. The rise in collaborative research initiatives further boosts innovation, with biotechnologies paving the way for more effective treatment options. However, the market faces challenges such as high treatment costs, a limited number of approved therapies, and regulatory hurdles which can stifle development pipelines. The potential opportunities lie in strategic partnerships, investing in personalized medicine, and exploring the untapped potential of emerging markets where awareness and diagnosis rates are low.

Nevertheless, limited awareness about NMOSD in developing regions and the complexity of clinical trials pose significant obstacles. For business growth, a promising area of innovation is the development of biomarkers for early detection, enhancing treatment efficacy, and patient outcomes. Insights into the market nature indicate a competitive landscape, primarily dominated by key pharmaceutical players with robust R&D capabilities and strategic alliances. Companies should focus on fostering collaboration across the healthcare ecosystem, optimizing supply chains, and increasing patient access through affordability programs to leverage these opportunities successfully.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Devic's Syndrome Treatment Market

The Devic's Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidences of Devic's Syndrome across the world
  • Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
  • Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
• Market Restraints
  • Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
• Market Opportunities
  • Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
  • Patient preference for personalized and specific treatment strategies
• Market Challenges
  • Possibility of side effects of the treatment solutions for Devic's Syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Devic's Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Devic's Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Devic's Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Devic's Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Devic's Syndrome Treatment Market

A detailed market share analysis in the Devic's Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Devic's Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Devic's Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Devic's Syndrome Treatment Market

A strategic analysis of the Devic's Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Devic's Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., Alexion Pharmaceuticals, Inc by AstraZeneca PLC, Anant Pharmaceuticals Pvt. Ltd., Apple Pharmaceuticals, Cadila Pharmaceuticals Limited, Chugai Pharma Taiwan Ltd., Conscientia Industrial Co., Ltd, Evidentic GmbH, F. Hoffmann-La Roche Ltd, Healthy Life Pharma Pvt. Ltd., Horizon Therapeutics plc by Amgen, Inc., LEXICARE PHARMA PVT. LTD., Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics, Inc., Samsung Bioepis Co., Ltd. by Samsung Biologics, Teva Pharmaceutical Industries Ltd., TG Therapeutics, Inc., Thermo Fisher Scientific Inc., and West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC.

Market Segmentation & Coverage

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Corticosteroids, Immunosuppressants, and Plasma Exchange (Plasmapheresis).
• Based on Distribution Channel, market is studied across Clinics, Hospitals, and Online Pharmacies.
• Based on End User, market is studied across Adult Patients and Pediatric Patients.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of Devic's Syndrome across the world
    • 5.1.1.2. Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
    • 5.1.1.3. Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
    • 5.1.3.2. Patient preference for personalized and specific treatment strategies
  • 5.1.4. Challenges
    • 5.1.4.1. Possibility of side effects of the treatment solutions for Devic's Syndrome
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
  • 5.2.2. End User: Development of a comprehensive Devic's Syndrome treatment plans for adult patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Devic's Syndrome Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Corticosteroids
• 6.3. Immunosuppressants
• 6.4. Plasma Exchange (Plasmapheresis)

7. Devic's Syndrome Treatment Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Clinics
• 7.3. Hospitals
• 7.4. Online Pharmacies

8. Devic's Syndrome Treatment Market, by End User

• 8.1. Introduction
• 8.2. Adult Patients
• 8.3. Pediatric Patients

9. Americas Devic's Syndrome Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Devic's Syndrome Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Devic's Syndrome Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope
  • 12.3.2. Health Canada Approves UPLIZNA for Adults with NMOSD
  • 12.3.3. Chugai Pharmaceutical's Enspryng Launches in Taiwan for NMOSD Patients
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Accord Healthcare, Inc.
• 2. Alexion Pharmaceuticals, Inc by AstraZeneca PLC
• 3. Anant Pharmaceuticals Pvt. Ltd.
• 4. Apple Pharmaceuticals
• 5. Cadila Pharmaceuticals Limited
• 6. Chugai Pharma Taiwan Ltd.
• 7. Conscientia Industrial Co., Ltd
• 8. Evidentic GmbH
• 9. F. Hoffmann-La Roche Ltd
• 10. Healthy Life Pharma Pvt. Ltd.
• 11. Horizon Therapeutics plc by Amgen, Inc.
• 12. LEXICARE PHARMA PVT. LTD.
• 13. Merck KGaA
• 14. Mitsubishi Tanabe Pharma Corporation
• 15. Opexa Therapeutics, Inc.
• 16. Samsung Bioepis Co., Ltd. by Samsung Biologics
• 17. Teva Pharmaceutical Industries Ltd.
• 18. TG Therapeutics, Inc.
• 19. Thermo Fisher Scientific Inc.
• 20. West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC